In Joo Kim

In Joo Kim


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in The World Journal of Men's Health
Verified
Journal Article
Open access
MSMyungjun Shin
Myungjun Shin
YJYun Kyung Jeon
Yun Kyung Jeon
IKIn Joo Kim
In Joo Kim
Shin MJ, et al. World J Mens Health. 2018 Jan;36:e14. https://doi.org/10.5534/wjmh.180001

13 February 2013 in Diabetes Care
Verified
Journal Article
Open access
PDF file
SKSang Soo Kim
Sang Soo Kim
SSSang Heon Song
Sang Heon Song
IKIn Joo Kim
In Joo Kim
YJYun Kyung Jeon
Yun Kyung Jeon
BKBo Hyun Kim
Bo Hyun Kim
YKYong Ki Kim
Yong Ki Kim
OBJECTIVE The aim of this study was to evaluate the association of urinary cystatin C, a tubular damage marker, with the progression of type 2 diabetic nephropathy. RESERCH DESIGN AND METHODS The baseline values of serum and urinary cystatin C were measured as primary parameters and those of urinary nonalbumin protein (NAP) were measured as secondary parameters. In this prospective observational study, a total of 237 type 2 diabetic patients were followed up for 29 months (13–44 months). RESULTS Both the urinary cystatin C-to-creatinine ratio (CCR) and NAP-to-creatinine ratio (NAPCR) were significantly different according to the degree of albuminuria. Both markers had strongly positive correlations at baseline. After adjusting for several clinical factors, both urinary CCR and NAPCR had significant associations with the decline of the estimated glomerular filtration rate (eGFR) (r = 0.160, P = 0.021; r = 0.412, P < 0.001, respectively). Urinary CCR had positive correlations with the decline of eGFR in the subpopulation of patients with eGFR ≥60 mL/min/1.73 m2. In patients with eGFR ≥60 mL/min/1.73 m2 and normoalbuminuria, only urinary NAPCR showed a significant association with the decline of eGFR; urinary CCR did not. In multivariate regression analysis, the number of patients who progressed to chronic kidney disease stage 3 or greater was higher in those in the upper tertiles of both the urinary levels of cystatin C and NAP than in those in the lower tertiles. CONCLUSIONS The results of this study suggest that urinary cystatin C and NAP may be predictors of the progression of type 2 diabetic nephropathy.

1 January 2011 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YJYun Kyung Jeon
Yun Kyung Jeon
MKMi Ra Kim
Mi Ra Kim
JHJung Eun Huh
Jung Eun Huh
JMJi Young Mok
Ji Young Mok
SSSang Heon Song
Sang Heon Song
IKIn Joo Kim
In Joo Kim
Jeon YK, et al. J Korean Med Sci. 2011 Feb;26(2):258-263. https://doi.org/10.3346/jkms.2011.26.2.258

9 May 2015 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
YJY. K. Jeon
Y. K. Jeon
MSM. J. Shin
M. J. Shin
MKM. H. Kim
M. H. Kim
JMJ. H. Mok
J. H. Mok
SKS. S. Kim
S. S. Kim
IKIn Joo Kim
In Joo Kim

29 November 2010 in Head & Neck
Verified
Journal Article
Closed access
PDF file
SKSang Soo Kim
Sang Soo Kim
BLByung Joo Lee
Byung Joo Lee
JLJin Choon Lee
Jin Choon Lee
SKSeong‐Jang Kim
Seong‐Jang Kim
YJYun Kyung Jeon
Yun Kyung Jeon
IKIn Joo Kim
In Joo Kim

1 January 2016 in Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
SKSang Soo Kim
Sang Soo Kim
JKJong Ho Kim
Jong Ho Kim
IKIn Joo Kim
In Joo Kim
Diabetes is often associated with chronic kidney disease (CKD) and is the primary cause of kidney failure in half of patients who receive dialysis therapy. Given the increasing prevalence of diabetes and its high morbidity and mortality, diabetic nephropathy is a serious drawback in individual patients and a tremendous socioeconomic burden on society. Despite growing concern for the management of diabetic nephropathy, the prevalence of CKD with diabetes is the same today as it was 20 years ago. The current strategy to manage diabetic nephropathy, including the control of hyperglycemia, dyslipidemia, and blood pressure and the wide-spread use of renin-angiotensin-aldosterone system inhibitors, is well established to be beneficial in the early stages of diabetic nephropathy. However, the effects are uncertain in patients with relatively progressed CKD. Therefore, early diagnosis or risk verification is extremely important in order to reduce the individual and socioeconomic burdens associated with diabetic nephropathy by providing appropriate management to prevent the development and progression of this condition. This review focuses on recent research and guidelines regarding risk assessment, advances in medical treatment, and challenges of and future treatments for diabetic nephropathy.